Nuvectra Corporation, a neurostimulation medical device company, develops and commercializes neurostimulation technology platform for the treatment of various disorders in neuroscience and clinical markets. The company offers Algovita, a spinal cord stimulation system for the treatment of chronic intractable pain of the trunk and limbs. It is also developing Virtis, a sacral neuromodulation (SNM) system for the treatment of chronic urinary retention and overactive bladder; and technologies to support other indications, including SNM for the treatment of overactive bladder and deep brain stimulation to treat Parkinson's disease.
Read More…
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Phone214-474-3103
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$48.83 million
Profitability
Miscellaneous
Employees197
Next Earnings Date11/4/2019 (Estimated)
OptionableOptionable
Nuvectra (NASDAQ:NVTR) Frequently Asked Questions
What is Nuvectra's stock symbol?
Nuvectra trades on the NASDAQ under the ticker symbol "NVTR."
How were Nuvectra's earnings last quarter?
Nuvectra Corp (NASDAQ:NVTR) issued its earnings results on Wednesday, July, 31st. The company reported ($0.62) EPS for the quarter, topping analysts' consensus estimates of ($0.81) by $0.19. The firm had revenue of $12.35 million for the quarter, compared to the consensus estimate of $12.42 million. Nuvectra had a negative return on equity of 58.23% and a negative net margin of 99.08%. View Nuvectra's Earnings History.
When is Nuvectra's next earnings date?
What price target have analysts set for NVTR?
3 Wall Street analysts have issued 12-month price targets for Nuvectra's shares. Their forecasts range from $4.00 to $18.00. On average, they anticipate Nuvectra's share price to reach $10.67 in the next twelve months. This suggests a possible upside of 645.9% from the stock's current price. View Analyst Price Targets for Nuvectra.
What is the consensus analysts' recommendation for Nuvectra?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nuvectra in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Nuvectra.
Has Nuvectra been receiving favorable news coverage?
Headlines about NVTR stock have trended somewhat negative recently, according to InfoTrie Sentiment. The research group rates the sentiment of news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Nuvectra earned a news impact score of -1.1 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Nuvectra.
Who are some of Nuvectra's key competitors?
Some companies that are related to Nuvectra include BRAINSWAY LTD/S (BWAY), Sensus Healthcare (SRTS), Liquidia Technologies (LQDA), Nephros (NEPH), Spectral Medical (EDTXF), Endologix (ELGX), Apollo Endosurgery (APEN), Pro-Dex (PDEX), AIT Therapeutics (AITB), Motus GI (MOTS), STRATA Skin Sciences (SSKN), BeyondAirInc . (XAIR), Nephros (NEPHD), Invo Bioscience (IVOB) and Arch Therapeutics (ARTH).
What other stocks do shareholders of Nuvectra own?
Who are Nuvectra's key executives?
Nuvectra's management team includes the folowing people:
- Dr. Fred B. Parks Ph.D., CEO & Director (Age 72)
- Mr. Joseph Paul Hanchin, Pres (Age 57)
- Mr. Walter Z. Berger, COO, CFO & Exec. VP (Age 63)
- Ms. Jennifer J. Kosharek, VP, Controller & Principal Accounting Officer (Age 38)
- Mr. Benjamin Tranchina, Chief Technology Officer
Who are Nuvectra's major shareholders?
Nuvectra's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Valeo Financial Advisors LLC (0.13%). Company insiders that own Nuvectra stock include Benjamin Tranchina, David D Johnson, Joseph Paul Hanchin and Thomas Edward Zelibor. View Institutional Ownership Trends for Nuvectra.
Which major investors are buying Nuvectra stock?
NVTR stock was purchased by a variety of institutional investors in the last quarter, including Valeo Financial Advisors LLC. Company insiders that have bought Nuvectra stock in the last two years include Benjamin Tranchina, David D Johnson and Thomas Edward Zelibor. View Insider Buying and Selling for Nuvectra.
How do I buy shares of Nuvectra?
Shares of NVTR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Nuvectra's stock price today?
One share of NVTR stock can currently be purchased for approximately $1.43.
How big of a company is Nuvectra?
Nuvectra has a market capitalization of $25.58 million and generates $48.83 million in revenue each year. The company earns $-48,130,000.00 in net income (profit) each year or ($3.19) on an earnings per share basis. Nuvectra employs 197 workers across the globe.View Additional Information About Nuvectra.
What is Nuvectra's official website?
How can I contact Nuvectra?
Nuvectra's mailing address is 5830 GRANITE PKWY SUITE 1100, PLANO TX, 75024. The company can be reached via phone at 214-474-3103 or via email at [email protected]
MarketBeat Community Rating for Nuvectra (NASDAQ NVTR)
MarketBeat's community ratings are surveys of what our community members think about Nuvectra and other stocks. Vote "Outperform" if you believe NVTR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVTR will underperform the S&P 500 over the long term. You may vote once every thirty days.
